Page last updated: 2024-11-06

5-methylhydantoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-methylhydantoin: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID69216
CHEMBL ID158019
CHEBI ID93888
SCHEMBL ID21767
MeSH IDM0137370

Synonyms (51)

Synonym
5-methylimidazolidine-2,4-dione
EN300-17026
2,4-imidazolidinedione, 5-methyl-
SPECTRUM_001906
2, 5-methyl-
nsc75829
5-methyl-2,4-imidazolidinedione
5-methylhydantoin
616-03-5
nsc-75829
hydantoin, 5-methyl-
SPECTRUM5_001760
5-methylhydantoin, 97%
KBIOSS_002442
KBIO2_005004
KBIO2_002436
KBIOGR_001899
KBIO3_001892
KBIO2_007572
SPECTRUM4_001200
SPECTRUM3_000916
DL-5-METHYLHYDANTOIN ,
M1699
67337-69-3
AKOS001074138
d-5-methylhydantoin
CHEMBL158019
inchi=1/c4h6n2o2/c1-2-3(7)6-4(8)5-2/h2h,1h3,(h2,5,6,7,8)
vmaqykgithdwkl-uhfffaoysa-
A833324
ai3-61188
nsc 75829
FT-0671817
FT-0671818
AM20100499
BRD-A68318914-001-01-5
FT-0620654
FT-0620655
CCG-214321
AKOS016050393
SCHEMBL21767
5-methyl-hydantoin
(d)-5-methylhydantoin
mfcd00022398
CHEBI:93888
Q27165643
CS-0084851
DTXSID90880934
PD000080
5-methy hydantoin
Z56862247
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID109516Anticonvulsant activity was evaluated by maximal electroshock seizure (MES) test at dose 600 mg/kg; No activity1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID109524Anticonvulsant activity was evaluated by subcutaneous pentylenetetrazole (Metrazol) (sc Met) seizure test at dose 600 mg/kg; No activity1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
AID109511Anticonvulsant activity was evaluated by Neurologic toxicity (the rotarod test) at dose 600 mg/kg; No activity1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Effect of structural modification of the hydantoin ring on anticonvulsant activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's3 (33.33)18.2507
2000's0 (0.00)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.78 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index20.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]